Add us as a preferred source
Dr. Lara Zibners, co-founder of Calla Lily Clinical Care, explains how rethinking vaginal drug delivery – not chasing new molecules – could reshape the fight against antibiotic resistance.
In Pitching The Future – A Healthcare Tomorrow podcast, a new audio series shining a light on medtech visionaries, we dig into the Eureka Moment behind their innovation, the wider problem it’s solving, and its potential impact on the future of healthcare.
This week, we’re joined by Dr. Lara Zibners, co-founder and chair of Calla Lily Clinical Care, a clinical-stage company pioneering vaginal drug delivery, with applications spanning fertility, menopause, cancer, and infectious disease.
Calla Lily has recently been selected for Wellcome Leap’s $50 million Focused Antibiotics programme – targeting a UTI treatment that spares the gut microbiome.
Lara is here to share why solving for women means solving for everybody, and how rethinking drug delivery – rather than chasing new molecules – could reshape the fight against antibiotic resistance…
